SLC5A2 and type 2 diabetes mellitus: Systemic RAAS has been shown to be activated transiently in patients with type 2 diabetes after beginning of SGLT2 inhibitors [39], whereas intrarenal RAAS is not activated after SGLT2 inhibition [40].